You're signed outSign in or to get full access.
Deerfield Management Company, L.P. (series C)
Deerfield Management Company, L.P. is a New York-based investment firm established in 1994, specializing in healthcare and life sciences investments. The firm manages a diversified portfolio encompassing over 150 private and public companies across sectors such as biotech, medical devices, diagnostics, digital health, and health services. Deerfield also engages in philanthropic initiatives through the Deerfield Foundation to enhance health equity and supports academic commercialization via collaborations with major research centers. Headquartered at 345 Park Avenue South, the firm employs between 150-200 people and serves institutional investors, healthcare companies, and innovators.
Investment Strategy
Deerfield Management Company, L.P. employs a research-driven investment strategy focused on healthcare and life sciences. The firm invests across all stages of company development—from early-stage startups to mature public companies—targeting sectors such as biotechnology, pharmaceuticals, diagnostics, medical devices, digital health, and health services. Deerfield seeks to create value by combining capital with expertise, supporting innovation that improves quality of life and reduces healthcare costs. The firm also leverages strategic partnerships and philanthropic initiatives to accelerate commercialization of novel technologies and drive societal impact in healthcare.
Latest 13F Filing Activity
Deerfield Management Company, L.P. (series C) filed their most recent 13F report on Jun 30, 2025 disclosing 113 equity positions with a total 13F market value of $6B. The fund increased holdings in Nuvalent Inc., Oscar Health Inc., United Therapeutics Corp. Del among other positions. Deerfield Management Company, L.P. (series C) reduced exposure to Alignment Healthcare Inc., Dynavax Technologies Corp., Chimerix Inc. among others.
Top Holdings
Equity Positions (113)
| Ticker | Security | Weight | Market Value | Shares | Avg Cost | Price | Change (QoQ) |
|---|---|---|---|---|---|---|---|
N NUVL | NUVALENT INC | 24.91% | $1.37B | 17,991,024 | $22.79 | $76.30 | +$96.8M |
O OSCR | OSCAR HEALTH INC | 4.53% | $249.8M | 11,649,591 | $11.50 | $21.44 | +$94.5M |
V VTRS | VIATRIS INC | 3.89% | $214.5M | 24,023,907 | $13.32 | $8.93 | +$5.6M |
M MRUS | MERUS N V | 3.23% | $178.0M | 3,384,628 | $32.12 | $52.60 | +$44.4M |
C CNC | CENTENE CORP DEL | 3.14% | $172.9M | 3,185,370 | $65.12 | $54.28 | +$10.7M |
Industry Allocation
Investment Team (36)
| Name | Role | Location | |
|---|---|---|---|
 | Partner | New York, NY , United States | |
B Brian Bizoza | Partner | New York, NY , United States | |
 | Partner, Head of Private Equity Capital Markets | New York, NY , United States | |
H Harshita Polishetty | Analyst | New York, NY , United States | |
J Jackson Harvey | Principal | New York, NY , United States | |
 | Partner | New York, NY , United States | |
J Jonathan Ramos | Principal | United States | |
K Ken Selle | Head Trader | Wheaton, IL , United States | |
K Konstantinos Aprilakis | Partner | New York, NY , United States | |
 | Associate | New York, NY , United States |
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more